Brainstorm Cell Therapeutics Secures $1M Financing for ALS Phase IIIb Trial
Mar 12, 2026
Brainstorm Cell Therapeutics announced a $1 million private placement at a premium to market price to support its upcoming Phase IIIb trial of NurOwn stem cell therapy for amyotrophic lateral sclerosis.